Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 23, Issue 4, 2008, Pages 549-555

  Tischle, Jessica L ^a   Abuaita, Basel ^a   Cuthpert, Sierra C ^a   Fage, Christopher ^a   Murphy, Kristi ^a   Saxe, Andrew ^b   Furr, Edward B ^c   Hedrick, Jamie ^c   Meyers, Jennifer ^c   Snare, David ^c   Zand, Ali R ^c  

^a UNIVERSITY OF MICHIGAN FLINT   (United States)

^b MCLAREN REGIONAL MEDICAL CENTER   (United States)

^c KETTERING UNIVERSITY   (United States)

Author keywords

Cancer; Histone deacetylase; Hydroxamic acid; Inhibitor; Short chain fatty acid

Indexed keywords

3 BENZOYLBENZOIC ACID HYDROXAMATE; 3 BENZOYLBENZOIC ACID N METHYLHYDROXAMATE; 3 BENZOYLBENZOIC ACID N,O DIMETHYLHYDROXAMATE; 3 BENZOYLPROPANOIC ACID HYDROXAMATE; 3 BENZOYLPROPANOIC ACID N METHYLHYDROXAMATE; 3 BENZOYLPROPANOIC ACID N,O DIMETHYLHYDROXAMATE; 4 BENZOYLBUTYRIC ACID N METHYLHYDROXAMATE; 4 BENZOYLBUTYRIC ACID N,O DIMETHYLHYDROXAMATE; 4 BENZOYLBUTYRIC HYDROXAMIC ACID; 4 PHENYLBUTYRIC ACID HYDROXAMATE; 4 PHENYLBUTYRIC ACID N METHYLHYDROXAMATE; 4 PHENYLBUTYRIC ACID N,O DIMETHYLHYDROXAMATE; 5 PHENYLVALERIC ACID N METHYLHYDROXAMATE; 5 PHENYLVALERIC ACID N,O DIMETHYLHYDROXAMATE; 5 PHENYLVALERIC HYDROXAMIC ACID; AMIDOHYDROLASE INHIBITOR; BUTYRIC ACID; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; SHORT CHAIN FATTY ACID; TRICHOSTATIN A; VORINOSTAT;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FLUOROMETRY; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ENZYME INHIBITORS; FATTY ACIDS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; RATS;

RATTUS;

EID: 48549085851     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701715703     Document Type: Article

References (31)

1. Strahl, BD and Allis, CD (2000) The language of covalent histone modifications. 403, pp. 41-45.
2. Grozinger, CM and Schreiber, SL (2002) Deacetylase enzymes: Biological functions and the use of small-molecule inhibitors. 9, pp. 3-16.
3. Rodriquez, M., Aquino, M., Bruno, I., De Martino, G., Taddei, M. and Gomez-Paloma, L. (2006) Chemistry and biology of chromatin remodeling agents: State of art and future perspectives of HDAC inhibitors. 13, pp. 1119-1139.
4. Yoshida, M., Hoshikawa, Y., Koseki, K., Mori, K. and Beppu, T. (1990) Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells. 43, pp. 1101-1106.
5. Vigushin, DM, Ali, S., Pace, PE, Mirsaidi, N., Ito, K., Adcock, I. and Coombesn, RC (2001) Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. 7, pp. 971-976.
6. Monneret, C. (2005) Histone deacetylase inhibitors. 40, pp. 1-13.
7. Sambucetti, L., Fischer, D., Zabludoff, S., Kwon, PO, Chamberlin, H., Trogani, N., Xu, H. and Cohen, D. (1999) Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. 274, pp. 34940-34947.
8. Richon, VM, Sandhoff, TW, Rifkind, RA and Mards, PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. 97, pp. 10014-10019.
9. Klisovic, DD, Katz, SE, Effron, D., Klisovic, MI, Wickham, J., Parthun, MR, Guimond, M. and Marcucci, G. (2003) Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. 44, pp. 2390-2398.
10. Finnin, MS, Donigian, JR, Cohen, A., Richon, VM, Rifkind, RA, Marks, PA, Breslow, R. and Pavietich, NP (1999) Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. 401, pp. 188-193.
11. Xie, A., Liao, C., Li, Z., Ning, Z., Hu, W., Lu, X., Shi, L. and Zhou, J. (2004) Quantitative structure-activity relationship study of histone deacetylase inhibitors. 4, pp. 273-299.
12. Nielsen, TK, Hildmann, C., Dickmanns, A., Schwienhorst, A. and Ficner, R. (2005) Crystal structure of a bacterial class 2 histone deacetylase homologue. 354, pp. 107-120.
13. Santini, V., Gozzini, A., Scappini, B., Grossi, A. and Ferrini, PR (2001) Searching for the magic bullet against cancer: The butyrate saga. 42, pp. 275-289.
14. Prasad, KN (1980) Butyric acid: A small fatty acid with diverse biological functions. 27, pp. 1351-1358.
15. Nguyen, TD, Kim, U-S and Perrine, SP (2006) Novel short chain fatty acids restore chloride secretion in cystic fibrosis. 342, pp. 245-252.
16. Phiel, CJ, Zhang, F., Huang, EY, Guenther, MG, Lazar, MA and Klein, PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer and teratogen. 276, pp. 36734-36741.
17. Suzuki, T. and Miyata, N. (2005) Non-hydroxamate histone deacetylase inhibitors. 12, pp. 2867-2880.
18. Gurvich, N., Tsygankova, OM, Meinkoth, JL and Klein, PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. 64, pp. 1079-1086.
19. Eyal, S., Yagen, B., Shimshoni, J. and Bialer, M. (2005) Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. 69, pp. 1501-1508.
20. Kuendgen, A., Knipp, S., Fox, F., Strupp, C., Hildebrandt, B., Steidl, C., Germing, U., Haas, R. and Gattermann, N. (2005) Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. 84, pp. 61-66.
21. Yoshida, M., Kijima, M., Akita, M. and Beppu, T. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. 265, pp. 17174-17179.
22. Yoshida, M., Kijima, M., Akita, M. and Beppu, T. (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. 265, pp. 17174-17179.
23. Amato, I. (2006) Pulling genes' strings. 84:29, pp. 13-20.
24. Qiu, L., Kelso, MJ, Hansen, C., West, ML, Fairlie, DP and Parsons, PG (1999) Anti-tumor activity in vitro and in vivo of selective differentiating agents containing hydroxamate. 80, pp. 1252-1258.
25. Nervi, C., Borello, U., Fazi, F., Buffa, V., Pelicci, PG and Cossu, G. (2001) Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. 61, pp. 1247-1249.
26. Whittaker, M., Floyd, CD, Brown, P. and Gearing, AJH (1999) Design and therapeutic application of matrix metalloproteinase inhibitors. 99 pp. 2735-2776.
27. Mulder, GJ and Meerman, JHN (1983) Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: The role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. 49, pp. 27-32.
28. Sanderson, L., Taylor, GW, Aboagye, EO, Alao, JP, Latigo, JR, Coombes, RC and Vigushin, DM (2004) Plasma pharmacokinetics and metabolism of the histone deacetylase inhibitor trichostatin A after intraperitoneal administration to mice. 32, pp. 1132-1138.
29. Wegener, D., Wirsching, F., Riester, D. and Schwienhorst, A. (2003) A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. 10, pp. 61-68.
30. Lea, MA, Shareef, A. and Sura, M. (2004) Induction of histone acetylation and inhibition of growth by phenyl alkanoic acids and structurally related molecules. 54, pp. 57-63.
31. Woo, SH, Frechette, S., Khalil, EA, Bouchain, G., Vaisburg, A., Bernstein, N., Moradei, O., Leit, S., Allan, M., Fournel, M., Trachy-Bourget, M-C, Li, Z., Besterman, JM and Delorme, D. (2002) Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. 45, pp. 2877-2885.